Registry collecting health information about Desmoplastic Small Round Cell Tumor

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry collects health information from individuals diagnosed with Desmoplastic Small Round Cell Tumor (DSRCT). The aim is to create a comprehensive database that enhances understanding of DSRCT and supports current and future research efforts. Participants of any age are encouraged to contribute their historical and longitudinal clinical data to aid in this initiative.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must have a diagnosis of desmoplastic small round cell tumor
* Participants may be of any age as long as the appropriate consent and assent may be obtained
* Willing to provide historical and longitudinal clinical data

Exclusion Criteria:

* Participant unwilling to provide consent or share historical and longitudinal clinical data

Where it's running

• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Emily Slotkin, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Emily Slotkin, MD
• Email: slotkine@mskcc.org
• Phone: 1-833-675-5437

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lurbinectedin plus irinotecan for advanced desmoplastic small round cell tumor

  This study will try lurbinectedin combined with irinotecan in people 15 and older whose desmoplastic small round cell tumor has come back or spread after anthracycline chemotherapy.

  Recruiting at 6 sites Phase 2 Italian Sarcoma Group · Candiolo, Torino and 10 other locations · NCT07328425

• Combining immune therapy with chemotherapy for advanced soft tissue sarcoma

  This study is testing if combining a new immune therapy with standard chemotherapy can help people with advanced soft tissue sarcoma who can’t have surgery or radiation feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06849986

• Testing a new drug combination for treating relapsed or refractory sarcomas in adolescents and young adults

  This study is testing a new combination of drugs to see if it can help adolescents and young adults with tough-to-treat sarcomas feel better and improve their chances of recovery.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06709495

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

• Using pasireotide to treat advanced synovial sarcoma and desmoplastic small round cell tumor

  This study is testing if the drug pasireotide can help young people with advanced synovial sarcoma and desmoplastic small round cell tumors stay healthy longer after their initial treatments.

  Recruiting Phase 2 University Hospital Heidelberg · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT06456359

• MASCT-I plus doxorubicin and ifosfamide as first-line treatment for advanced soft tissue sarcoma

  This trial will test whether adding MASCT-I to standard chemotherapy (doxorubicin and ifosfamide) helps adults with advanced soft tissue sarcoma respond better or live longer.

  Recruiting Phase 2 HRYZ Biotech Co. · Guangzhou · NCT06277154

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.